Literature DB >> 29696352

[Allergic emergencies].

A-C Herr1, T Biedermann1, K Brockow2.   

Abstract

Both anaphylactic reactions and angioedema in the head and neck area can be life-threatening and require emergency treatment. Therapy needed is primarily directed by the patient's symptoms. The first measures taken should consist of immediate disruption of the allergen contact, adequate positioning of the patient, the insertion of an intravenous catheter and an emergency call. In case of cardiovascular or respiratory involvement, intramuscular ± inhalative adrenalin is the treatment of choice. In case of cardiovascular involvement, volume substitution by intravenous catheter and oxygen administration are crucial and in lower airway obstruction, additionally short-acting beta mimetics should be inhaled. Intravenous H1-antihistamines and glucocorticoids are added. Allergic reaction confined to the skin and mucosal surfaces without respiratory involvement or to the gastrointestinal tract should also be treated with intravenous H1-antihistamines and glucocorticoids. Angioedema in the head and neck area can, however, also be associated with a life-threatening upper airway obstruction. Histamine-induced angioedema should be treated as anaphylaxis involving the upper respiratory tract. In hereditary angioedema, or in unclassified angioedema unresponsive to therapy, early airway maintenance and subcutaneous injection of bradykinin-receptor antagonist icatibant, intravenous injection of C1-inhibitor concentrate or fresh frozen plasma is recommended. The same approach should be taken for severe angiotensin converting enzyme inhibitor-induced angioedema with dyspnea. Intubation by skilled personal is indicated in inspiratory stridor and dyspnea at rest. In all cases of anaphylaxis or angioemdema, patients should be surveyed until a safe remission is achieved.

Entities:  

Keywords:  Adrenaline; Anaphylaxis; Angioedema; Angiotensin converting enzyme inhibitors; Therapy

Mesh:

Substances:

Year:  2018        PMID: 29696352     DOI: 10.1007/s00105-018-4163-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  19 in total

1.  [Allergy--triggers of life-threatening and fatal anaphylaxis].

Authors:  K Brockow; J Ring
Journal:  MMW Fortschr Med       Date:  2006-07-20

Review 2.  Recurrent angioedema and the threat of asphyxiation.

Authors:  Konrad Bork
Journal:  Dtsch Arztebl Int       Date:  2010-06-11       Impact factor: 5.594

3.  Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease.

Authors:  D E Dean; D L Schultz; R H Powers
Journal:  J Forensic Sci       Date:  2001-09       Impact factor: 1.832

Review 4.  Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema.

Authors:  R A Sabroe; A K Black
Journal:  Br J Dermatol       Date:  1997-02       Impact factor: 9.302

5.  Symptom profile and risk factors of anaphylaxis in Central Europe.

Authors:  M Worm; G Edenharter; F Ruëff; K Scherer; C Pföhler; V Mahler; R Treudler; R Lang; K Nemat; A Koehli; B Niggemann; S Hompes
Journal:  Allergy       Date:  2012-02-16       Impact factor: 13.146

Review 6.  Anaphylaxis: acute treatment and management.

Authors:  Johannes Ring; Martine Grosber; Matthias Möhrenschlager; Knut Brockow
Journal:  Chem Immunol Allergy       Date:  2010-06-01

Review 7.  Off-Label Use of Agents for Management of Serious or Life-threatening Angiotensin Converting Enzyme Inhibitor-Induced Angioedema.

Authors:  Colleen M Culley; Julie N DiBridge; Gregory L Wilson
Journal:  Ann Pharmacother       Date:  2015-09-28       Impact factor: 3.154

8.  Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.

Authors:  Hugh A Sampson; Anne Muñoz-Furlong; Ronna L Campbell; N Franklin Adkinson; S Allan Bock; Amy Branum; Simon G A Brown; Carlos A Camargo; Rita Cydulka; Stephen J Galli; Jane Gidudu; Rebecca S Gruchalla; Allen D Harlor; David L Hepner; Lawrence M Lewis; Phillip L Lieberman; Dean D Metcalfe; Robert O'Connor; Antonella Muraro; Amanda Rudman; Cara Schmitt; Debra Scherrer; F Estelle R Simons; Stephen Thomas; Joseph P Wood; Wyatt W Decker
Journal:  J Allergy Clin Immunol       Date:  2006-02       Impact factor: 10.793

9.  Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.

Authors:  K Brockow; C Jofer; H Behrendt; J Ring
Journal:  Allergy       Date:  2008-02       Impact factor: 13.146

Review 10.  The epidemiology of anaphylaxis in Europe: a systematic review.

Authors:  S S Panesar; S Javad; D de Silva; B I Nwaru; L Hickstein; A Muraro; G Roberts; M Worm; M B Bilò; V Cardona; A E J Dubois; A Dunn Galvin; P Eigenmann; M Fernandez-Rivas; S Halken; G Lack; B Niggemann; A F Santos; B J Vlieg-Boerstra; Z Q Zolkipli; A Sheikh
Journal:  Allergy       Date:  2013-10-14       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.